Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 97

1.

What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews.

Makady A, de Boer A, Hillege H, Klungel O, Goettsch W; (on behalf of GetReal Work Package 1).

Value Health. 2017 Jul - Aug;20(7):858-865. doi: 10.1016/j.jval.2017.03.008. Epub 2017 May 11. Review.

PMID:
28712614
2.

Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.

Makady A, Ham RT, de Boer A, Hillege H, Klungel O, Goettsch W; GetReal Workpackage 1.

Value Health. 2017 Apr;20(4):520-532. doi: 10.1016/j.jval.2016.12.003. Epub 2017 Jan 27. Review.

PMID:
28407993
3.

The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries.

Kleijnen S, Leonardo Alves T, Meijboom K, Lipska I, De Boer A, Leufkens HG, Goettsch WG.

Qual Life Res. 2017 Apr 11. doi: 10.1007/s11136-017-1574-9. [Epub ahead of print]

PMID:
28401419
4.

The HTA Core Model®-10 Years of Developing an International Framework to Share Multidimensional Value Assessment.

Kristensen FB, Lampe K, Wild C, Cerbo M, Goettsch W, Becla L.

Value Health. 2017 Feb;20(2):244-250. doi: 10.1016/j.jval.2016.12.010.

PMID:
28237203
5.

Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making.

Schneeweiss S, Eichler HG, Garcia-Altes A, Chinn C, Eggimann AV, Garner S, Goettsch W, Lim R, Löbker W, Martin D, Müller T, Park BJ, Platt R, Priddy S, Ruhl M, Spooner A, Vannieuwenhuyse B, Willke RJ.

Clin Pharmacol Ther. 2016 Dec;100(6):633-646. doi: 10.1002/cpt.512. Epub 2016 Oct 19.

PMID:
27627027
6.

Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.

Kleijnen S, Lipska I, Leonardo Alves T, Meijboom K, Elsada A, Vervölgyi V, d'Andon A, Timoney A, Leufkens HG, De Boer A, Goettsch WG.

Ann Oncol. 2016 Sep;27(9):1768-75. doi: 10.1093/annonc/mdw233. Epub 2016 Jun 20.

PMID:
27329251
7.

Review of Policies And Perspectives on Real-World Data for Drug Development and Assessment (Imi-Getreal Deliverable).

Makady A, Goettsch W.

Value Health. 2015 Nov;18(7):A567. doi: 10.1016/j.jval.2015.09.1863. Epub 2015 Oct 20. No abstract available.

8.

Eunethta Members: What are their Roles within the National Setting?

Diekmann S, Krüger LJ, Warren DS, Goettsch W.

Value Health. 2015 Nov;18(7):A562. doi: 10.1016/j.jval.2015.09.1833. Epub 2015 Oct 20. No abstract available.

9.

The Use Of Social Media To Generate Health Data For Effectiveness Research: A Scoping Review.

Kalf R, Makady A, Meijboom K, Goettsch W.

Value Health. 2015 Nov;18(7):A471. doi: 10.1016/j.jval.2015.09.1247. Epub 2015 Oct 20. No abstract available.

10.

Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments.

Kleijnen S, Fathallah M, van der Linden MW, Vancraeynest P, Dahmani B, Timoney A, De Boer A, Leufkens HG, Goettsch WG.

Value Health. 2015 Jul;18(5):663-72. doi: 10.1016/j.jval.2015.03.1790. Epub 2015 Jun 10.

11.

Impact of high-fat diet and voluntary running on body weight and endothelial function in LDL receptor knockout mice.

Langbein H, Hofmann A, Brunssen C, Goettsch W, Morawietz H.

Atheroscler Suppl. 2015 May;18:59-66. doi: 10.1016/j.atherosclerosissup.2015.02.010.

PMID:
25936306
12.

Piloting international production of rapid relative effectiveness assessments of pharmaceuticals.

Kleijnen S, Pasternack I, Rannanheimo P, Vuola JM, Van de Casteele M, Bucsics A, Pulis IZ, Di Bidino R, Sacchini D, Montilla S, Abrishami P, Sammut SM, Muscolo LA, Happonen P, Goettsch WG.

Int J Technol Assess Health Care. 2014 Nov;30(5):521-9. doi: 10.1017/S0266462314000622.

PMID:
25747562
13.

Standardized reporting for rapid relative effectiveness assessments of pharmaceuticals.

Kleijnen S, Pasternack I, Van de Casteele M, Rossi B, Cangini A, Di Bidino R, Jelenc M, Abrishami P, Autti-Rämö I, Seyfried H, Wildbacher I, Goettsch WG.

Int J Technol Assess Health Care. 2014 Nov;30(5):488-96. doi: 10.1017/S0266462314000609.

PMID:
25747557
14.

European collaboration on relative effectiveness assessments: What is needed to be successful?

Kleijnen S, Toenders W, de Groot F, Huic M, George E, Wieseler B, Pavlovic M, Bucsics A, Siviero PD, van der Graaff M, Rdzany R, Kristensen FB, Goettsch W.

Health Policy. 2015 May;119(5):569-76. doi: 10.1016/j.healthpol.2015.01.018. Epub 2015 Feb 7. Review.

15.

From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.

Eichler HG, Baird LG, Barker R, Bloechl-Daum B, Børlum-Kristensen F, Brown J, Chua R, Del Signore S, Dugan U, Ferguson J, Garner S, Goettsch W, Haigh J, Honig P, Hoos A, Huckle P, Kondo T, Le Cam Y, Leufkens H, Lim R, Longson C, Lumpkin M, Maraganore J, O'Rourke B, Oye K, Pezalla E, Pignatti F, Raine J, Rasi G, Salmonson T, Samaha D, Schneeweiss S, Siviero PD, Skinner M, Teagarden JR, Tominaga T, Trusheim MR, Tunis S, Unger TF, Vamvakas S, Hirsch G.

Clin Pharmacol Ther. 2015 Mar;97(3):234-46. doi: 10.1002/cpt.59. Epub 2015 Feb 4.

PMID:
25669457
16.

Applicability Of Eunethta Relative Effectiveness Assessment of Pazopanib For National Assessments.

Kleijnen S, Leufkens HG, Boer A, Goettsch W, Fathallah M.

Value Health. 2014 Nov;17(7):A661-2. doi: 10.1016/j.jval.2014.08.2428. Epub 2014 Oct 26. No abstract available.

17.

Increased gene expression of the cardiac endothelin system in obese mice.

Catar RA, Muller G, Brandt A, Langbein H, Brunssen C, Goettsch C, Frenzel A, Hofmann A, Goettsch W, Steinbronn N, Strasser RH, Schubert U, Ludwig B, Bornstein SR, Morawietz H.

Horm Metab Res. 2015 Jun;47(7):509-15. doi: 10.1055/s-0034-1387761. Epub 2014 Sep 2.

PMID:
25181417
18.

Improving the contribution of regulatory assessment reports to health technology assessments--a collaboration between the European Medicines Agency and the European network for Health Technology Assessment.

Berntgen M, Gourvil A, Pavlovic M, Goettsch W, Eichler HG, Kristensen FB.

Value Health. 2014 Jul;17(5):634-41. doi: 10.1016/j.jval.2014.04.006. Epub 2014 Jun 30.

19.

Review: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.

Goettsch WG, Enzing J.

Value Health. 2014 Jan-Feb;17(1):1-2. doi: 10.1016/j.jval.2013.09.003. Epub 2013 Oct 31. No abstract available.

Supplemental Content

Loading ...
Support Center